These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22333485)

  • 1. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Nicolaides M; Richard A; Xiang Z; Armbrecht J; Pfeffer MA;
    J Renin Angiotensin Aldosterone Syst; 2012 Sep; 13(3):387-93. PubMed ID: 22333485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.
    Smink PA; Hoekman J; Grobbee DE; Eijkemans MJ; Parving HH; Persson F; Ibsen H; Lindholm L; Wachtell K; de Zeeuw D; Heerspink HJ
    Eur J Prev Cardiol; 2014 Apr; 21(4):434-41. PubMed ID: 23467676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.
    Heerspink HJ; Ninomiya T; Persson F; Brenner BM; Brunel P; Chaturvedi N; Desai AS; Haffner SM; Mcmurray JJ; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2016 Feb; 18(2):169-77. PubMed ID: 26511599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
    N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advantages and limitations of renin inhibition with aliskiren].
    Azizi M; Frank M; Steichen O; Blanchard A
    Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
    Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Hans-Henrik P
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):118-21. PubMed ID: 21824990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
    Persson F; Rossing P; Reinhard H; Juhl T; Stehouwer CD; Schalkwijk C; Danser AH; Boomsma F; Frandsen E; Parving HH
    Diabetes Care; 2009 Oct; 32(10):1873-9. PubMed ID: 19587362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial.
    Wu MT; Tung SC; Hsu KT; Lee CT
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):271-7. PubMed ID: 23223162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.